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The objectives of the  Final Degree Project are: 
A.  to compile those moonlighting proteins associated with genetic diseases or 
disorders, which appear because of a mutation that occur in the human gene of 
each protein, and to join, as an update, into the database of multitasking protein 
(multitaskProtDB), where researchers will be able to find out quickly and easily the 
information they are looking for.  
B. Identify and specify which proteins are known drug targets and, if possible, what 
different kind of side effect could be attributable to the different functions they have.   
 REFERENCES:   
 
[1] Copley SD (2012) Moonlighting is mainstream: paradigm adjustment required. Bioessays, 34:578-588.  
[2] Gómez A, Domedel N, Cedano J, Piñol J, Querol E. (2003) Do current sequence analysis algorithms disclose multifunctional (moonlighting) proteins?. Bioinformatics, 19:895-896.  
[3] Gómez A, Hernández S, Amela I, Piñol J, Cedano J, Querol E. (2011) Do protein-protein interaction databases identify moonlighting proteins? Mol Biosyst, 7:2379-2382.  
[4] Jeffery CJ (2011) Proteins with neomorphic moonlighting functions in disease. IUBMB Life, 63:489-494.  
[5] Hernández S, Ferragut G, Amela I, Perez-Pons J, Piñol J, Mozo-Villarias A, Cedano J, Querol E. (2014) MultitaskProtDB: a database of multitasking proteins. Nucleic Acids Res., 42: D517-520.  
[6] Butler GS, Overall CM. (2009) Proteomic identification of multitasking proteins in unexpected locations complicates drug targeting. Nat Rev Drug Discov, 8:935-948  
PubMed (www.ncbi.nlm.nih.gov/pubmed) 
Following: moonlighting, multitasking, bioinformatics, disease, disorders, 
drug  targeting and drug side effects.   
 
Databases:   
• MultitaskProtDB (http://wallace.uab.es/multitask/) 
• Online Mendelian Inheritance in Man (OMIM) (http://www.ncbi.nlm.nih.gov/omim/)    
• Human Gene Mutation Database” (HGMD, http://www.hgmd.org/) 
• The Drug Gene Interaction Database (http://dgidb.genome.wustl.edu/)  
• Side Effect Resource (SIDER) http://sideeffects.embl.de/ 
 
We have used only the Homo sapiens moonlighting proteins and it has been built a 
table with the disorders related, the drugs and the side effects 
Multifunctional or multitasking proteins, also named moonlighting proteins, 
are proteins with more than one function. The first function ever disclosed of 
the protein is named  canonical function and the other discovered lately are 
moonlighting functions.  
 
These proteins complicate the interpretation of knock-outs/ knock-ins, DNA 
arrays, metabolomics and  systems biology analyses, drug targeting, drug 
pharmacokinetics, pharmacodynamics and  toxicity assays, etc [1,2].  
 
Generally, they are discovered by serendipity while investigating  other 
issues, but it would be useful to find other methods to to identify moonlighting 
proteins. An approach is bioinformatics analyses, although the final 
demonstration remains experimental. The bioinformatics approach has been 
the objective of the group of Bioinformatics for Molecular Biology, which 
supervises this End-of-Degree Project [3, 4] which has also created the first 
database of these proteins [5].  
 
There are some examples of proteins  in which the second function is not a 
“normal” function and are involved in different diseases (Neomorphic 
Moonlighting Function, gain-of-toxic-function) [6].  
 
Thus, the complex phenotypes of several disorders may be related to the 
involvement of moonlighting proteins. A major challenge associated with 
therapeutic manipulation of moonlight protein is designing a drug which 
inhibits the function involved in the pathology while minimizing disruption of 
the other functions [2]. 
4. RESULTS 
PROTEIN NAME UNIPROT DISEASE DRUG TARGET SIDE EFFECTS 
Aconitase  Q71UF1 Infantile cerebellar-retinal degeneration (MIM number 614559) 
4-hydroxy-aconitate ion 
Aconitase ion 
Alpha-methylisocitric acid 
Tricarballylic acid 
Cytoplasmatic aconitate hydratase/IRP1  P21399 Association with myophathy (MIM number 255125) 
hCNT1 (Sodium/nucleoside cotransporter 1) O00337 Concentrative nucleoside transporter deficiency Anthracyclines and related substances 
ATF2 protein (Cyclic AMP-dependent transcription factor)  P15336 
Cytochrome c P99999 Thrombocytopaenia 4 (MIM number 612004) 
Heme 
Heme C 
Minocycline (negative modulador) sideeffects.embl.de/drugs/4200/ 
N-trimethyllysine 
Protoporphyrin IX containing Co or Zn 
Zinc substituted heme C 
DLD (Dyhidrolipoyl dehydrogenase, mitochondrial)  P09622  Dihydrolipoamide dehydrogenase deficiency (MIM number 246900) 
Flavin-adenine dinucleotide   
NADH 
Nicotinamide-adenine-dinucleotide   
ERK (signal-regulated kinases, MAPK1)  P28482 Truncus arteriosus (MIM number  217095) 
Arsenic trioxide (inducer) sideeffects.embl.de/drugs/14888/ 
Isoproterenol (inducer) sideeffects.embl.de/drugs/3779/ 
Sorafenib sideeffects.embl.de/drugs/216239/ 
ERK2.txt 
Enolase (Gamma enolase)  P09104 2-Phosphoglycolic acid 
hRoDH-E2 (Dehydrogenase/  
reductase SDR family member 9) 
Q9BPW9 
La protein (Lupus La protein) P05455 
Association with Sjogren syndrome (MIM number 270150) 
Association with systemic lupus erythematosus (SLE; MIM number 152700) 
Amelogenin Q99217 
Amelogenesis imperfecta, hypoplastic/ hypomaturation type 1E (MIM number 
301200) 
Gpx4  (Glutathione peroxidase-4) P36969 Increased 5-lipoxygenase metabolism Glutathione (cofactor) 
Phosphoglucose isomerase  P06744 
Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase 
deficiency (MIM number 613470) 
5-Phospho-D-arabinohydroxamic acid 
5-Phsphoarabinonic acid 
6-Phosphogluconic acid 
Alpha-D-glucose-phosphate 
PGI deficiency, autosomal recessive (MIM number 172400) 
Erythose-4-phosphate 
Fructose-6-phosphate 
Glucose-6-phosphate 
  Sorbitol 6-phosphate 
Thymidine phosphorylase  P19971 
Mitochondrial DNA depletion syndrome 1 (MNGIE type; MIM number 603041) 
5-Chloro-6-[(2-Iminopyrrolidin-1-
yl)methyl]pyrimidine-2,4(1H,3H)-dione 
Peripheral neuropathy with intestinal pseudo-occlusion Fluorouracil sideeffects.embl.de/drugs/3385/ 
Neuropilin (VEGF receptor) O14786 
Anti-NRP1 (inhibitor) 
Palifermin 
Pegaptanib sideeffects.embl.de/drugs/158786/ 
Glyceraldehyde-3-phosphate dehydrogenase P04406 
Huntington disease (MIM number 143100) 4-(2-Aminoethyl)benzenesulfonyl fluoride 
Alzheimer disease (MIM number 104300 and 104310) Adenosine-5-diphosphoribose 
 Parkinson disease (MIM number168601) NADH 
Brain ischemia Nicotinamide-adenine-dinucleotide 
  Thiocotinamide-adenine-dinucleotide 
PMS2 mismatch-repair enzyme P54278 
Colorectal cancer, hereditary nonpolyposis, type 4 (MIM number  614337)   
Mismatch repair cancer Syndrome (MIM number 276300) Adenosine-5'-diphosphate 
Colorectal adenoma Phosphothiophosphoric acid-adenylate ester 
Defective protein-protein interaction with MLH1   
Neuroectodermal tumors and cafe-au-lait spots   
CFTR chloride channel (Cystic fibrosis 
 transmembrane conductance regulator)  
P13569 
Congenital bilateral absence of vas deferens (MIM number 277180)   
Cystic fibrosis (MIM number 219700) Adenosine-5'-diphosphate 
Sweat chloride elevation without CF Bumetanide (antagonist) sideeffects.embl.de/drugs/2471/ 
 Modifier of Bronchiectasis with or without elevated sweat chloride 1 (MIM 
number 211400) 
Glyburide (antagonist) sideeffects.embl.de/drugs/3488/ 
Neonatal hypertrypsinemia; Idiopathic Pancreatitis (MIM number 167800) Ivacaftor (potentiator) 
Fetal hyperechogenic bowel Phosphoaminophosphonic acid-adenylate ester 
Primary sclerosing cholangitis Phosphonoserine 
Association with respiratory/pancreatic disease     
Association with Typhoid fever (protection against)   
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Figures 2. Percentage of moonlighting proteins that have a disease or diseases-associated (A), that are drug target (B) and that have 
drugs with side effects (C). Distribution of the different types of canonical  functions (D) or moonlighting functions (E) in the human 
moonlighting proteins associated with diseases. Distribution of the different types of disorders in the human moonlighting proteins (F).  
Glycerol Kinase  P32189 Glycerol kinase deficiency (or hyperglycerolemia; MIM number 307030) 
Isocitrate dehydrogenase  Q13584 D-2-hydroxyglutaric aciduria 2 (MIM number  613657) Isocitric acid 
Succinyl-coA synthetase (Succinate thiokinase) P53597 
Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with 
methylmalon aciduria; MIM number 245400) Succinic acid 
Succinyl-coenzyme A synthetase deficiency 
Succinate dehydrogenase  O14521 
Cowden syndrome 3 (MIM number 615106)     
Carcinoid tumors, intestinal (MIM number 114900) 
2-Hexyloxy-6-hydroxymethyl-tetrahydro-pyran-
3,4,5-triol 
  
Merkel cell carcinoma, somatic Hexachlorophene (inhibitor) sideeffects.embl.de/drugs/3598/  
Paraganglioma and gastric stromal sarcoma (MIM number  606864) Succinic acid   
Paragangliomas 1, with or without deafness (MIM number 168000) Ubiquinone-1   
Pheochromocytoma (MIM number 171300)     
Fumarate hydratase  P07954 
Fumarase deficiency (MIM number 606812) 
Leiomyomatosis and renal cell cancer (HLRCC; MIM number 150800) 
Leydig cell tumour of the testis 
Ovarian mucinous cystadenoma 
Ku70/Ku80 P13010 Association with Bladder cancer (increased risk) Thalidomide sideeffects.embl.de/drugs/5426/ 
Xanthine oxidoreductase  Q9UH91 Xanthinuria type I (or XDH Deficiency; MIM number 278300) 
4-[5-PYRIDIN-4-YL-1H-[1,2,4]TRIAZOL-3-YL]-
PYRIDINE-2-CARBONITRILE 
Allopurinol sideeffects.embl.de/drugs/2094/ 
Dioxothuomolybdenum (VI) ion   
Doxorubicin sideeffects.embl.de/drugs/1690/ 
Febuxostat sideeffects.embl.de/drugs/134018/ 
Flavin-adenine dinucleotide   
L-carnitine sideeffects.embl.de/drugs/85/ 
Leptin 
Y-700 
ERCC2 - TFIIH basal transcription factor c 
omplex helicase XPD  subunit  
P18074 
Cerebrooculafacioskeletal syndrome 2 (MIM number 610756) Doxorubicin sideeffects.embl.de/drugs/1690/ 
Trichothiodystrophy (MIM number 601675) Ifosfamide sideeffects.embl.de/drugs/3690/ 
Xeroderma pigmentosum group D (MIM number  278730) Leucovorin sideeffects.embl.de/drugs/143/ 
Association with oligodendroglioma development (reduce risk) Methotrexate sideeffects.embl.de/drugs/4112/ 
Cockayne syndrome (MIM number 216400) Oxaliplatin sideeffects.embl.de/drugs/4609/ 
  Platinum compound   
  Vitamin C   
E 
A D 
• From 288 moonlighting proteins in the database MultitaskProtDB, only 91 of them are human proteins. That means 
around 30% of all multitasking proteins which have been described until nowadays. There are 69% of them which 
have diseases associated or have susceptibility to a disorder. These suggest that moonlighting proteins are more 
prone to be involved in human disease than the average. Although unknown what percentage of the estimated 1-5 
million proteins in the human proteome it is difficult to think in about 70% of them involved in pathology.   
 
• Of these human moonlighting proteins involved in pathology, more than 75% are proteins whose canonical function 
is involved in the metabolism or in the replication, transcription and translation or in the cell structure or cytoskeleton 
interactions, whilst these functions as moonlighting ones are found in 55%. Concluding that it has been an increase 
of the other functions and also from the category “others” from 3,2% to 12,7%, where are included the proteins with 
more than one category of functions.  
 
• According to the clinical disorder, 62% of the diseases can be classified into neurological disorders, different ks of 
cancer and metabolic disorders (30,7%, 22,3% and 9%, respectively).   
 
• 54% of these 91 proteins are drug targets, what mean that there are 49 proteins on which may act different drugs in 
which there are also included the substrates.  
 
• But, up to now, only 27% of the human moonlighting proteins have been associated side effects related to some of 
the drugs that act in the protein. Future work will be gaining insight into the side effects at molecular level.  
 
In conclusion, with the information that has been compiled of moonlighting proteins, we can contribute to identify 
molecular mechanisms of diseases, and to understand why some side effects appear linked  to some drugs. 
 
The above shown results will be included in the next update of the mentioned MultitaskProtDB database.   
 
 
Table 1.  Some of the 91 human moonlighting proteins that are found in the database MultitaskProtDB.  
Figures 3. Side effects which appears in Side Effect Resource Webside (SIDER).  (A) Ibuprofen, a drug that acts in cyclooxygenase-1 gene (COX-1). 
 (B) Fluorouracil, a drug that acts in thymidine phosphorylase (marked with a brown arrow), thymidylate synthase and endothelial nitric oxide synthase.   
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Figure 1.  Glyceraldehyde-3P-dehydrogenase, a moonlighting protein with 13 functions. 
Table 2. Disease, drugs and side effects links of the human moonlighting proteins that appear in Table 1.  
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